|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/20 | (2006.01) |
| A61K 38/2013 | (2013.01) | ||
| A61P 35/00 | (2006.01) | ||
| A61K 38/2086 | (2013.01) | ||
| A61P 35/00 | (2018.01) |
| (11) | Number of the document | 3359182 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16791713.7 |
| Date of filing the European patent application | 2016-10-07 | |
| (97) | Date of publication of the European application | 2018-08-15 |
| (45) | Date of publication and mention of the grant of the patent | 2023-04-19 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/US2016/056088 |
| Date | 2016-10-07 |
| (87) | Number | WO 2017/062832 |
| Date | 2017-04-13 |
| (30) | Number | Date | Country code |
| 201562239207 P | 2015-10-08 | US |
| (72) |
CHARYCH, Deborah , US
KIRK, Peter , GB
|
| (73) |
Nektar Therapeutics ,
455 Mission Bay Boulevard South
Suite 100, San Francisco, CA 94158,
US
|
| (54) | COMBINATION OF AN IL-2RBETA-SELECTIVE AGONIST AND A LONG-ACTING IL-15 AGONIST |
| COMBINATION OF AN IL-2RBETA-SELECTIVE AGONIST AND A LONG-ACTING IL-15 AGONIST |